9, 30 An alternative to changing the dose is to change the frequency of dosing; 33, 34 for example, it has recently been reported that patients whose acromegaly is well-controlled with lanreotide Autogel 120 mg every 4 weeks may be able to have their dose interval extended to every 6 8 weeks without loss of efficacy.
Items 2 g ("changing the dose when the doctor changes the prescription" and 2 h ("using the needle guard") followed a skip pattern, where subjects who did not have a dose change or did not use the needle guard skipped these items.
Six attributes demonstrated significant differences in scores between the two injection pens (mixing the medicine, remembering the dose prescribed by the doctor, changing the dose when the doctor changes the prescription, using the needle guard, knowing when the injection pen has finished injecting the medicine, and handling the injection pen while preparing and injecting the medicine).
All but 4 attributes (setting the dose, changing the dose when the doctor changes the prescription, handling the injection pen while preparing and injecting the medicine, and storing the injection pen in the refrigerator) demonstrated significant differences in scores between the two injection pens.
The attributes are: attaching/removing needle, preparing the injection pen, mixing the medicine, removing the air bubbles, remembering the dose, setting the dose, changing the dose for prescription changes, using the needle guard, injecting the medicine, knowing when the injection was finished, handling the pen, storing the pen, disposing of the cartridge/pen and "overall ease of use".
Serious adverse events were defined as those that resulted in any change to the anti-TB drug regimen, either changing the dose of a drug, or temporarily or permanently removing a drug from the regimen.
For instance, changing the dose-weighted elimination half-life of ∑DDT from its lowest value (4.1 years) to the highest value (6 years) increases the modeled concentration by a factor of 6/4.1 = 1.46.
Likewise, the areal dose-rate can be changed either by changing the total dose-rate for a fixed illumination area, or by changing the illumination area at a fixed total dose-rate by spreading or contracting the electron beam using the lower condenser lenses.
Changing the MSLMOD dose by only twofold causes an approximately 100-fold change in male viability normalised to sisters of the same genotype.
Control of the resistivity and UV-Vis transparency of the films was achieved by changing the aluminium dose in the film, the preparation temperature and the composition of the plasma (O2 H2 ratio).
Therefore, we conducted our dose response analysis, like those reported in previous studies, by observing changes in end-tidal sevoflurane concentration during emergence instead of by recording EEG while systematically changing the anesthetic dose during induction.
